Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?
Targeting oncogenes and their interactive partners is an effective Boots Men’s approach to developing novel targeted therapies for cancer and other chronic diseases.We and others have long suggested the MDM2 oncogene being an excellent target for cancer therapy, based on its p53-dependent and -independent oncogenic activities in a variety of canc